US Markets

By boat and on foot, Indian state hunts for plasma for COVID patients

Credit: REUTERS/ANUWAR HAZARIKA

When doctors in a flood-ravaged Indian state urgently sought plasma of a particular blood type for a COVID-19 patient this month, health officials sent a boat for a marooned donor who had recovered from the disease weeks ago.

By Krishna N. Das and Zarir Hussain

GUWAHATI, India, July 27 (Reuters) - When doctors in a flood-ravaged Indian state urgently sought plasma of a particular blood type for a COVID-19 patient this month, health officials sent a boat for a marooned donor who had recovered from the disease weeks ago.

With coronavirus cases surging in the northeastern state of Assam and critical medicines running low, local authorities are rolling out the red carpet for now-cured patients - all for their blood plasma believed to be rich in virus antibody, although research on its efficacy has not been conclusive.

Assam says that symptomatic patients who donate plasma four weeks after recovery will get preference in government jobs and housing. For example, a donor may get extra marks if he or she is tied in any test or interview for a job.

It is also offering to cover travel and other expenses for donors from outside the state, and has been making its frontline workers scour the state - sometimes wading through flood waters - to bring willing participants to plasma donation centres.

The success of the overall effort is crucial for Assam, one of India's poorest states that is short of remdesivir and tocilizumab to treat severe COVID-19 patients. Delhi and Odisha states are also courting plasma donors as India's total infections have leaped to 1.4 million with nearly 33,000 deaths.

"Recently, we wanted O-group plasma for a patient, a doctor," Assam Health Minister Himanta Biswa Sarma told Reuters in an interview.

"When we learned that a person was willing to donate, people went to his house by boat, brought him to the hospital and got the donation done."

He declined to identify the donor but said the recipient was doing well.

Plasma from a previously infected person can be used to treat up to two moderately ill patients, Sarma said. Without timely treatment, such patients' condition can potentially worsen, further straining the limited pool for medicines.

"We have seen that if you give plasma between moderate and critical stage, the results are very, very good," he said.

GREY MARKET

Assam, where floods have so far killed around 100 people and affected roughly 3 million, is predicting coronavirus infections will peak in mid-September. It has so far reported more than 32,000 cases with 79 deaths.

Its push for plasma comes as India, the world's biggest suppliers of generic drugs, scrambles to end a local shortage of remdesivir and tocilizumab.

Although U.S. drugmaker Gilead Sciences Inc GILD.O has authorised six companies operating in India to make and sell generic versions of remdesivir, only three of them have so far been able to start making supplies available.

Sarma said that until recently, Assam was receiving only 12-16 remdesivir vials a day, compared with a demand for at least 100. But the situation eased when Assam got 400 vials from a local company some days ago, he said.

"Still, people are not doing enough production and obviously a grey market has emerged as a result," Sarma said.

(Reporting by Krishna N. Das and Zarir Hussain in Guwahati; Editing by Sanjeev Miglani and Raju Gopalakrishnan)

((Krishna.Das@tr.com; +91 987111 8314;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More